Cited 0 times in
11C-Acetate PET/CT for Reactive Astrogliosis Outperforms 11C-Methionine PET/CT in Glioma Classification and Survival Prediction
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강석구 | - |
dc.contributor.author | 김세훈 | - |
dc.contributor.author | 윤미진 | - |
dc.contributor.author | 장종희 | - |
dc.contributor.author | 전중현 | - |
dc.contributor.author | 김동우 | - |
dc.date.accessioned | 2024-03-22T07:03:49Z | - |
dc.date.available | 2024-03-22T07:03:49Z | - |
dc.date.issued | 2024-02 | - |
dc.identifier.issn | 0363-9762 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/198673 | - |
dc.description.abstract | Purpose: 11C-acetate (ACE) PET/CT visualizes reactive astrogliosis in tumor microenvironment. This study compared 11C-ACE and 11C-methionine (MET) PET/CT for glioma classification and predicting patient survival. Patients and methods: In this prospective study, a total of 142 patients with cerebral gliomas underwent preoperative MRI, 11C-MET PET/CT, and 11C-ACE PET/CT. Tumor-to-contralateral cortex (TNRMET) and tumor-to-choroid plexus ratios (TNRACE) were calculated for 11C-MET and 11C-ACE. The Kruskal-Wallis test and Bonferroni post hoc analysis were used to compare the differences in 11C-TNRMET and 11C-TNRACE. The Cox proportional hazards regression analysis and classification and regression tree models were used to assess progression-free survival (PFS) and overall survival (OS). Results: The median 11C-TNRMET and 11C-TNRACE for oligodendrogliomas (ODs), IDH1-mutant astrocytomas, IDH1-wildtype astrocytomas, and glioblastomas were 2.75, 1.40, 2.30, and 3.70, respectively, and 1.40, 1.20, 1.77, and 2.87, respectively. The median 11C-TNRMET was significantly different among the groups, except between ODs and IDH1-wildtype astrocytomas, whereas the median 11C-TNRACE was significantly different among all groups. The classification and regression tree model identified 4 risk groups (IDH1-mutant with 11C-TNRACE ≤ 1.4, IDH1-mutant with 11C-TNRACE > 1.4, IDH1-wildtype with 11C-TNRACE ≤ 1.8, and IDH1-wildtype with 11C-TNRACE > 1.8), with median PFS of 52.7, 44.5, 25.9, and 8.9 months, respectively. Using a 11C-TNRACE cutoff of 1.4 for IDH1-mutant gliomas and a 11C-TNRACE cutoff of 2.0 for IDH1-wildtype gliomas, all gliomas were divided into 4 groups with median OS of 52.7, 46.8, 27.6, and 12.0 months, respectively. Significant differences in PFS and OS were observed among the 4 groups after correcting for multiple comparisons. Conclusions: 11C-ACE PET/CT is better for glioma classification and survival prediction than 11C-MET PET/CT, highlighting its potential role in cerebral glioma patients. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Lippincott | - |
dc.relation.isPartOf | CLINICAL NUCLEAR MEDICINE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Acetates | - |
dc.subject.MESH | Astrocytoma* | - |
dc.subject.MESH | Brain Neoplasms* / diagnostic imaging | - |
dc.subject.MESH | Brain Neoplasms* / pathology | - |
dc.subject.MESH | Glioma* / diagnostic imaging | - |
dc.subject.MESH | Glioma* / pathology | - |
dc.subject.MESH | Gliosis | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Inflammation | - |
dc.subject.MESH | Methionine | - |
dc.subject.MESH | Mutation | - |
dc.subject.MESH | Positron Emission Tomography Computed Tomography | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Racemethionine | - |
dc.subject.MESH | Tumor Microenvironment | - |
dc.title | 11C-Acetate PET/CT for Reactive Astrogliosis Outperforms 11C-Methionine PET/CT in Glioma Classification and Survival Prediction | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Neurosurgery (신경외과학교실) | - |
dc.contributor.googleauthor | Dongwoo Kim | - |
dc.contributor.googleauthor | Ju Hyeon Yi | - |
dc.contributor.googleauthor | Youngjoo Park | - |
dc.contributor.googleauthor | Sun Jung Kim | - |
dc.contributor.googleauthor | Seok-Gu Kang | - |
dc.contributor.googleauthor | Se Hoon Kim | - |
dc.contributor.googleauthor | Joong-Hyun Chun | - |
dc.contributor.googleauthor | Jong Hee Chang | - |
dc.contributor.googleauthor | Mijin Yun | - |
dc.identifier.doi | 10.1097/rlu.0000000000004991 | - |
dc.contributor.localId | A00036 | - |
dc.contributor.localId | A00610 | - |
dc.contributor.localId | A02550 | - |
dc.contributor.localId | A03470 | - |
dc.contributor.localId | A05406 | - |
dc.relation.journalcode | J00595 | - |
dc.identifier.eissn | 1536-0229 | - |
dc.identifier.pmid | 38049976 | - |
dc.identifier.url | https://journals.lww.com/nuclearmed/fulltext/2024/02000/11c_acetate_pet_ct_for_reactive_astrogliosis.1.aspx | - |
dc.contributor.alternativeName | Kang, Seok Gu | - |
dc.contributor.affiliatedAuthor | 강석구 | - |
dc.contributor.affiliatedAuthor | 김세훈 | - |
dc.contributor.affiliatedAuthor | 윤미진 | - |
dc.contributor.affiliatedAuthor | 장종희 | - |
dc.contributor.affiliatedAuthor | 전중현 | - |
dc.citation.volume | 49 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 109 | - |
dc.citation.endPage | 115 | - |
dc.identifier.bibliographicCitation | CLINICAL NUCLEAR MEDICINE, Vol.49(2) : 109-115, 2024-02 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.